TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Stopped early · Phase 1/Phase 2
Conditions studied: Sarcoma, Ewing
In brief
Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to establish initial safety and efficacy data in monotherapy and in combination with vincristine to assess the potential of TK216 for further development.
Key facts
- Study ID
- NCT02657005
- Run by
- Oncternal Therapeutics, Inc
- People needed
- 85
- Starts
- 2016-08-01
- Expected to finish
- 2022-06-01
- Last updated by the study team
- 2025-02-12
Who can join
Age: 8 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California, United States
- Children's Hospital of Colorado — Aurora, Colorado, United States
- Children's National Hospital — Washington D.C., District of Columbia, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Duke Cancer Institute — Durham, North Carolina, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Texas Children's Cancer & Hematology Centers, Baylor College — Houston, Texas, United States
- UT MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.